Role of nanotechnology in targeted drug delivery and imaging: a concise review

被引:494
作者
Koo, Otilia M. [1 ]
Rubinstein, Israel [1 ,2 ,3 ]
Onyuksel, Hayat [1 ,4 ]
机构
[1] Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL USA
[2] Univ Illinois, Dept Med, Chicago, IL USA
[3] Jesse Brown Vet Affairs Med Ctr, Chicago, IL USA
[4] Univ Illinois, Dept Bioengn, Chicago, IL USA
基金
美国国家卫生研究院;
关键词
Nanotechnology; Targeted drug delivery; Imaging; Systemic administration;
D O I
10.1016/j.nano.2005.06.004
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
The use of nanotechnology in drug delivery and imaging in vivo is a rapidly expanding field. The emphases of this review are on biophysical attributes of the drug delivery and imaging platforms as well as the biological aspects that enable targeting of these platforms to injured and diseased tissues and cells. The principles of passive and active targeting of nanosized carriers to inflamed and cancerous tissues with increased vascular leakiness, overexpression of specific epitopes, and cellular uptake of these nanoscale systems are discussed. Preparation methods-properties of nanoscale systems including liposomes, micelles, emulsions, nanoparticulates, and dendrimer nanocomposites, and clinical indications are outlined separately for drug delivery and imaging in vivo. Taken together, these relatively new and exciting data indicate that the future of nanomedicine is very promising, and that additional preclinical and clinical studies in relevant animal models and disease states, as well as long-term toxicity studies, should be conducted beyond the bproof-of-conceptQ stage. Large-scale manufacturing and costs of nanomedicines are also important issues to be addressed during development for clinical indications. (C) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:193 / 212
页数:20
相关论文
共 213 条
[41]   Extravasation of poly(amidoamine) (PAMAM) dendrimers across microvascular network endothelium [J].
El-Sayed, M ;
Kiani, MF ;
Naimark, MD ;
Hikal, AH ;
Ghandehari, H .
PHARMACEUTICAL RESEARCH, 2001, 18 (01) :23-28
[42]   EXTRACELLULAR PH DISTRIBUTION IN HUMAN TUMORS [J].
ENGIN, K ;
LEEPER, DB ;
CATER, JR ;
THISTLETHWAITE, AJ ;
TUPCHONG, L ;
MCFARLANE, JD .
INTERNATIONAL JOURNAL OF HYPERTHERMIA, 1995, 11 (02) :211-216
[43]   Nanopartide-aptamer bioconjugates: A new approach for targeting prostate cancer cells [J].
Farokhzad, OC ;
Jon, SY ;
Khademhosseini, A ;
Tran, TNT ;
LaVan, DA ;
Langer, R .
CANCER RESEARCH, 2004, 64 (21) :7668-7672
[44]   Cancer nanotechnology: Opportunities and challenges [J].
Ferrari, M .
NATURE REVIEWS CANCER, 2005, 5 (03) :161-171
[45]  
Fetterly GJ, 2003, AAPS PHARMSCI, V5
[46]   Endothelial barriers: from hypothetical pores to membrane proteins [J].
Firth, JA .
JOURNAL OF ANATOMY, 2002, 200 (06) :541-548
[47]   Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: Comparison with the corresponding antibody-enzyme conjugate [J].
Fonseca, MJ ;
Jagtenberg, JC ;
Haisma, HJ ;
Storm, G .
PHARMACEUTICAL RESEARCH, 2003, 20 (03) :423-428
[48]   Ligand-targeted liposomes [J].
Forssen, E ;
Willis, M .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 29 (03) :249-271
[49]   Test of a two-pathway model for small-solute exchange across the capillary wall [J].
Fu, BM ;
Adamson, RH ;
Curry, FE .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1998, 274 (06) :H2062-H2073
[50]   A novel delivery system for amphotericin B with lipid nano-sphere (LNS®) [J].
Fukui, H ;
Koike, T ;
Saheki, A ;
Sonoke, S ;
Seki, J .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 265 (1-2) :37-45